Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$0.22 - $0.66 $22,000 - $66,000
100,000 Added 454.55%
122,000 $47,000
Q3 2023

Nov 14, 2023

SELL
$0.2 - $1.78 $17,300 - $153,970
-86,500 Reduced 79.72%
22,000 $4,000
Q3 2022

Nov 14, 2022

BUY
$1.02 - $1.26 $88,230 - $108,990
86,500 Added 393.18%
108,500 $132,000
Q2 2022

Aug 15, 2022

BUY
$0.91 - $2.01 $20,020 - $44,219
22,000 New
22,000 $22,000

Others Institutions Holding OTLK

About Outlook Therapeutics, Inc.


  • Ticker OTLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 226,144,992
  • Market Cap $1.17B
  • Description
  • Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...
More about OTLK
Track This Portfolio

Track Ancora Advisors, LLC Portfolio

Follow Ancora Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ancora Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ancora Advisors, LLC with notifications on news.